Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
about
HCV Kinetic Models and Their Implications in Drug DevelopmentClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CHepatitis C virus: Virology, diagnosis and treatmentFinding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactionsLiver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patientsImpaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care.Predictive factors associated with hepatitis C antiviral therapy response.A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C.Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis.Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.The role of HCV proteins on treatment outcomes.Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada.Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients.Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy.[Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy].
P2860
Q26801602-3CEE93CC-A679-4509-BC2C-61243DD087B5Q28080225-3FB872EA-DEF4-4B9B-9467-82856D9C58D7Q28082000-D26F078D-FD29-4B79-B46C-15F1E5ED865AQ28543010-2003C5C9-678E-4E41-A2F0-569E3BD19F85Q33889885-D1A662F9-C338-4520-ACFA-8D50398042D8Q34271143-B64BFA8D-8C1F-4C03-B5D4-01F24E5F28C5Q34467208-0F672FC9-3DBC-4848-B3E6-CC0CD3C85854Q35602958-D2E7A2CA-8CFA-4890-A76A-C8EF03515873Q35790397-0317C36F-ABFE-4395-9A97-663228A6BED3Q36165241-510536B9-F40B-4A97-A9B6-F34B3BD410D7Q36297087-9362436E-64E4-4100-A5CF-CA3AA73C23CAQ37703064-54360CD6-55BA-46BB-ADE0-C03CB33825B8Q38594613-465A3A48-82EA-4E1E-B7EC-09F989B36073Q38668968-FFE5A6B2-E71D-4552-BF8F-93316DB75FECQ39692527-4D1F91B4-F3C2-440C-BA2F-F665B7FC2950Q41932931-586D4BE5-8AE8-4553-ABC6-000A3A40E993Q42175503-BA40A03C-CF3B-4740-BC2F-F47796B6318BQ50270442-A7A63803-1D16-4487-9D34-41FA416944F9
P2860
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@ast
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@en
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@nl
type
label
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@ast
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@en
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@nl
prefLabel
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@ast
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@en
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@nl
P2860
P3181
P356
P1476
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy
@en
P2093
P2860
P304
P3181
P356
10.3748/WJG.V19.I47.8963
P407
P577
2013-12-21T00:00:00Z